SecBot SecBot
8-K ·Filed Nov 9, 2026

HRTX

HERON THERAPEUTICS, INC. /DE/
NEUTRAL
Impact 6/10
Horizonmonths Processed7d 20h ago SEC0001193125-26-452672
8-K material event: Items 1.01
Actionable Insight • Neutral

The transaction transforms Heron from a commercial-stage biotech with product revenue into a cash-rich entity with a significant equity stake in CorMedix and contingent royalty/earn-out streams. Monitor the proxy filing for stockholder vote timing and any competing acquisition proposals. Post-close, focus on CorMedix's commercial execution of the acquired products, particularly ZYNRELEF's sales trajectory toward the earn-out thresholds.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

HRTX drug pipeline →

ZYNRELEF

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.
Next catalyst
None dated

What to watchZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.3706
T+0 close · Nov 9, 2026 · via day close
Latest settled
−23.29%
T+5 · $0.2843
Vs SPY
−21.59%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $0.3706entry
  2. T+1 · 7d ago +0.94%α +1.31% · $0.3741
  3. T+5 · 21h ago −23.29%α −21.59% · $0.2843
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Heron Therapeutics (HRTX) entered into a definitive asset purchase agreement to sell its commercial-stage anti-nausea and post-operative pain product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix Inc. (CRMD) for $145M in cash plus 14,583,333 CRMD shares, along with tiered royalty payments on CINVANTI/SUSTOL net sales above a $25M threshold and earn-out payments on ZYNRELEF up to $55M. Concurrently, Heron exchanged its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, effectively deleveraging its balance sheet. The transaction requires Heron stockholder approval and is expected to close within six months.

Key Financial Metrics

Deal Value
$145.0M
Deal Type
acquisition

Key Facts

  • Heron sells its commercial product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix for $145M cash plus 14,583,333 CRMD shares (Stock Consideration).
  • Heron exchanges its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, eliminating that debt.
  • Heron is eligible for 5% royalty payments on CINVANTI/SUSTOL net sales above a $25M annual threshold for calendar years 2027-2029.
  • Heron is eligible for earn-out payments on ZYNRELEF: $25M if 2028 net sales reach $65M, plus $30M if they reach $95M (max $55M).
  • Heron stockholders must approve the transaction; closing conditions include antitrust clearance and Nasdaq listing of the CRMD shares.
  • Heron will retain its corporate existence and certain excluded assets; the deal is structured as a taxable asset sale.
  • Heron enters into a governance agreement with CorMedix, including board designation rights while ownership exceeds 10%.
  • Heron agrees to a 5-year non-compete in the Field (aprepitant/granisetron injectables for nausea, bupivacaine/meloxicam for post-op pain).
  • CorMedix has secured debt financing from BioPharma Credit PLC to fund the cash consideration.

Financial Impact

$145M base cash consideration plus 14,583,333 CRMD shares (value dependent on CRMD stock price at close), plus potential royalties and earn-outs up to $55M

revenuedebtdilutioncash

Risk Factors

  • Transaction requires Heron stockholder approval and antitrust clearance; failure would leave Heron with its current debt and product portfolio.
  • Heron's post-close value is tied to CorMedix stock performance and the success of the acquired products, over which Heron has no operational control.
  • Earn-out payments on ZYNRELEF are contingent on achieving aggressive net sales targets ($65M-$95M in 2028) and are not guaranteed.
  • The non-compete restricts Heron from re-entering the nausea/pain injectable market for five years.
  • CorMedix's ability to fund the cash consideration depends on its debt financing from BioPharma Credit PLC.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452672
Document: hrtx-ex10_3.htm0001193125-26-452672
Document: hrtx-ex10_4.htm0001193125-26-452672
Document: hrtx-ex10_2.htm0001193125-26-452672

Track record

15 reports on HRTX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
  2. Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  3. Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  4. Nov 9, 20267d ago 8-K Neutral 6/10 Viewing Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  5. Nov 9, 20267d ago Press Release Mixed 7/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
  6. Aug 10, 202614w ago 8-K Bearish 7/10 No price data
  7. Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
  8. Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
  9. Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
  10. May 11, 202627w ago 8-K Bearish 6/10 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens in 5h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026